A trial for my life
Article Abstract:
A cancer survivor describes her experience participating in a clinical trial sponsored by the National Cancer Institute that provided free treatment for her stage IV Hodgkin's disease. The author encourages other people with cancer to join clinical trials so the cancer rate will be reduced. Less than 5% of cancer patients participate in clinical trials. If 10% participated, the length of the trials could be cut from several years to one year. A benefit the author derived from participating in the clinical trial was having a team of oncologists treat her case rather than only one private oncologist. Although she encountered some problems with an allergic reaction to one of the medications, she decided to stay in the trial and continue with the three other medications she had been taking. She recovered. Cancer patients who would like to participate in clinical trials should call 800-4-CANCER.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Moxibustion for Correction of Breech Presentation: A Randomized Controlled Trial
Article Abstract:
Moxibustion appears to increase fetal activity in breech fetuses, leading to spontaneous turning to the normal position. Moxibustion is a traditional Chinese medicine used to treat breech pregnancies that uses burning herbs to stimulate acupuncture point BL 67, which is located beside the outer corner of the fifth toenail. Researchers randomly assigned 260 pregnant women in their 33rd week to receive moxibustion for 7-14 days or routine care. Women in the moxibustion group counted more fetal movements on average than the other women. Seventy-five percent of the fetuses in the moxibustion group turned, compared to 48% in the other group.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Efficacy of Tremacamra, a Soluble Intercellular Adhesion Molecule 1, for Experimental Rhinovirus Infection: A Randomized Clinical Trial
Article Abstract:
The drug tremacamra appears to reduce the symptoms of cold and may prevent colds entirely. Tremacamra is a form of the intercellular adhesion molecule 1 (ICAM-1), which is a cell receptor that cold viruses bind to. Therefore, the drug should stop the virus from infecting cells. Researchers randomly assigned 177 healthy volunteers to receive tremacamra or a placebo and then exposed them to rhinoviruses, which cause most colds. Over 85% of the people in both groups became infected but those who took tremacamra were less likely to develop a cold and also had fewer symptoms when they did.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Oral cobalamin for treatment of pernicious anemia? A Structured Teaching and Self-management Program for Patients Receiving Oral Anticoagulation: A Randomized Controlled Trial
- Abstracts: Treatment of Irritable Bowel Syndrome With Chinese Herbal Medicine: A Randomized Controlled Trial. Irritable bowel syndrome
- Abstracts: Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial
- Abstracts: Effect of iodophor vs iodine tincture skin preparation on blood culture contamination rate. New blood cancer therapies under study
- Abstracts: Rural primary care. Cross-Cultural Primary Care: A Patient-Based Approach. The effects of organizational structure on primary care outcomes under managed care